Date: December 13, 2007

Voluntary Recall of Specific Lots of Haemophilus Influenzae type b (Hib) Vaccine

Merck & Co., Inc. ("Merck") has initiated a voluntary recall in the United States of 10 lots of PedvaxHIB® and 2 lots of COMVAX® due to the discovery of *Bacillus cereus* during routine testing of vaccine manufacturing equipment. Sterility tests of the vaccine lots themselves have not found any contamination. As a precautionary measure, Merck has sent a letter to health care providers who may have received the affected vaccine lots.

Individuals who received vaccine from these lots do not need to be revaccinated since no potency concerns have been identified for these vaccine lots. However, these individuals should complete their immunization series with a Haemophilus b conjugate-containing vaccine not affected by this recall. Affected doses were distributed beginning in April 2007. No other lots of PedvaxHIB® or COMVAX® and no other Merck products are affected by this recall.

Additional information, including a list of the lots being recalled, is available on the CDC website www.cdc.gov/vaccines in a section called *In the Spotlight*. The first two items (Current supply of vaccine and Q&As) deal with the HIB recall and list lot numbers. For further questions, local healthcare providers may also contact the County of San Diego Immunization Branch at (619) 692-8661.

Thank you for your continued participation.

Emergency Medical Alert Network (EMAN)
County of San Diego, Health & Human Services Agency
Community Epidemiology Branch